Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556394 | 1.00 | TACR1 (0.51) | TACR1SIGMAR1GRIN1GRIN2BCHRM3 | |
| SCHEMBL13674458 | 0.79 | TACR1 (0.52) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL6041583 | 0.78 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL1618266 | 0.78 | TACR1 (0.61) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL6340896 | 0.77 | TACR1 (0.48) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL31193852 | 0.77 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL5870998 | 0.77 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL1339508 | 0.77 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL28164936 | 0.77 | TACR1 (0.59) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 | |
| SCHEMBL24575781 | 0.77 | TACR1 (0.50) | TACR1SIGMAR1GRIN1GRIN2BCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | TACR1 508/4885SIGMAR1 3885/4885GRIN1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.